1,771 results on '"Perez, Edith A"'
Search Results
152. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer
153. Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers
154. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
155. miR-221-5p-Mediated Downregulation of JNK2 Aggravates Acute Lung Injury
156. 784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors
157. Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
158. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
159. 5-Year Follow-Up of a Randomized Controlled Trial of Immediate Versus Delayed Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Breast Cancer Starting Letrozole After Tamoxifen: N03CC (Alliance) Trial
160. Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
161. Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy: An NCCTG-97-24-51 Based Study
162. Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
163. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
164. Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends
165. Comprehensive Diagnostic Program for Medically Underserved Women With Abnormal Breast Screening Evaluations in an Urban Population
166. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
167. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
168. Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study
169. White matter properties underlying reading abilities differ in 8-year-old children born full term and preterm
170. Diversity, Equity, and Inclusion in Nursing
171. Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1
172. Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors
173. Abstract CT133: Results of phase I study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple negative breast cancer
174. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
175. The tale of TILs in breast cancer:A report from The International Immuno-Oncology Biomarker Working Group
176. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials
177. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study
178. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)
179. Patient Age and Preoperative Breast MRI in Women With Breast Cancer: Biopsy and Surgical Implications
180. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies
181. Expert Roundtable: Emerging Questions in ErbB2-Positive Breast Cancer; February 22, 2007
182. Cardiac Toxicity of ErbB2-Targeted Therapies: What Do We Know?
183. Novel Taxane Formulations in the Treatment of Breast Cancer: A Thought Leader Discussion and Consensus Roundtable
184. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
185. North Central Cancer Treatment Group—Achievements and Perspectives
186. Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
187. Metastasectomy and Surgical Resection of the Primary Tumor in Patients With Stage IV Breast Cancer: Time for a Second Look?
188. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
189. Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy
190. Adjuvant therapy of triple negative breast cancer
191. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
192. Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization
193. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012)
194. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
195. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
196. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
197. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways
198. Treatment of metastatic breast cancer: looking towards the future
199. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer
200. Adjuvant chemotherapy in older women with early-stage breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.